TEAM
Alex Zhavoronkov, PhD
Founder and CEO, Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (8th annual in 2021) the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Min Fang
Managing Director of Healthcare, Warbrug Pincus
Min Fang is based in Shanghai, joined Warburg Pincus in 2007 and focuses on investments in the Healthcare sector in Asia. Prior to joining Warburg Pincus, he worked at the Boston Consulting Group focusing on Management Consulting for pharmaceutical and medical device companies. Mr. Fang is a Director of Beijing Amcare Women's and Children's Hospital Group, HTDK (Shanghai) Co., Ltd., Evercare (Beijing) Holding Group Co. Ltd, Shanghai Haihe Pharmaceutical Co., Ltd., Hygeia Medical Service Group (6078.HK) and Jinxin Fertility Group (1951.HK). He received a B.A. of International Finance from Fudan University and an M.B.A. from the Stanford Graduate School of Business.
Kan Chen
Principal, Qiming Venture Partners
Mr. Kan Chen is a Principal of Qiming Venture Partners, focusing on healthcare investment.
Before joining Qiming Venture Partners, Kan was a senior scientist at Johnson&Johnson discovering innovative cancer medicine. Prior to that, Kan was a group leader at Jiangsu Hengrui Medicine, developing new cancer immunotherapies.
Kan earned his PhD degree in Cell Biology from Case Western Reserve University in the U.S. and finished his postdoctoral training in Immunology at Harvard Medical School. He got his bachelor's degree in biological sciences from Fudan University.
Steven Kenneth Galson
Independent Director, Insilico Medicine
Dr. Galson served as the senior vice president, research and development at Amgen. Prior to joining Amgen in 2010, where he also led regulatory affairs, Dr. Galson spent more than 20 years in public service roles across the U.S. Department of Health and Human Services (HHS), Department of Energy (DOE), Environmental Protection Agency (EPA) and Centers for Disease Control and Prevention (CDC). From 2001 to 2007, Dr. Galson progressed from deputy director, to acting director, to director of CDER at the FDA. From 2007 to 2009 he served as acting surgeon general of the United States.
Feng Ren, PhD
CEO and Head of R&D, Insilico Medicine
Dr. Feng Ren received his Ph.D. degree in chemistry from Harvard University in 2007. He then spent 11 years in the discovery and development of small molecule innovative drugs at GlaxoSmithKline (GSK), where he served as the principal scientist, program leader, director and head of chemistry of Neurodegeneration DPU, a global drug R&D unit in neurosciences in GSK. In 2018, Dr. Ren joined Medicilon, a contract research organization (CRO) providing drug discovery services to the biopharmaceutical companies globally, where he served as senior Vice President and head of the drug R&D service business of the Chemistry Department and Biology Department with over 600 chemists and biologists. In 2021, Dr. Ren joined Insilico Medicine as CSO, responsible for internal pipelines and external collaborations in drug discovery and development. In his career Dr. Ren successfully developed multiple preclinical candidate compounds/clinical phase I compounds for the treatment of non-small cell lung cancer, multiple sclerosis, psoriasis, inflammatory bowel disease, Parkinson's disease, and neuropathic pain. Dr. Ren published over 30 peer-reviewed papers and over 20 patents.
Robert Spiegel, PhD
Former Chief Medical Officer, Schering-Plough
Following a fellowship at the National Institutes of Health (NIH) in medical oncology, Dr. Spiegel was the Director of Developmental Therapeutics at NYU Cancer Center and then spent over 25 years at Schering-Plough (now Merck & Co.), where he joined as the first Director for Oncology Clinical Research, and subsequently held a series of senior executive positions, including SVP Worldwide Clinical Development and Chief Medical Officer from 1998-2010. He led the development of Intron A (interferon alpha), Temodar® (temozolomide), and Remicade® (infliximab), and was involved with approval of over 30 New Drug Applications by the FDA. Dr. Spiegel has been a consultant to the biotech industry and has served on the scientific advisory board and board of directors of multiple biotech companies. He received his undergraduate degree, cum laude, from Yale University and his medical degree from the University of Pennsylvania.
Lennart Lee
Charles Cantor, PhD
Former Chief Scientific Officer, Sequenom;
Former principal scientist of Human Genome Project
After more than 40 years in academia holding positions in chemistry and human genetics & development at Columbia University, molecular biology at the University California Berkeley, and biomedical engineering and pharmacology at Boston University, Dr. Cantor switched to the private sector where he co-founded Sequenom - the company that first commercialized non invasive prenatal testing, and Retrotope, a clinical stage pharmaceutical company using deuterated essential nutrients as drugs.
Michael Levitt, PhD
Professor, Stanford University;
Winner of the Nobel Prize in Chemistry (2013)
Michael Levitt is a Nobel Prize-winning biophysicist who has conducted pioneering work on the molecular structure of essential biological compounds. He has made many significant contributions to the study of protein folding and helped to popularise the use of computer modelling in biology.
Amongst the foremost of Michael's numerous scientific achievements is his development of the first computerised model of an enzyme reaction, which was subsequently expanded to simulate more generalised protein dynamics. He has also carried out important research on the modelling of antibodies as well as DNA and messenger RNA — work that has informed practical advances in biomedical science.
Michael has received many honours and awards for his research, including the 2013 Nobel Prize in Chemistry and the 2014 DeLano Award for Computational Biosciences. A member of the US National Academy of Sciences, since 1987 he has been a Professor of Structural Biology at Stanford University.
Dr. Kai-Fu Lee
Chairman and CEO, Sinovation Ventures
President, Sinovation Ventures Artificial Intelligence Institute
Sinovation Ventures, managing US$2.5 billion dual currency investment funds, is a leading venture capital firm focusing on developing the next generation of Chinese high-tech companies. Prior to founding Sinovation in 2009, Dr. Lee was the President of Google China, and senior executives at Microsoft, SGI, and Apple. Dr. Lee received his Bachelor degree from Computer Science from Columbia University, Ph.D. from Carnegie Mellon University, as well as Honorary Doctorate Degrees from both Carnegie Mellon and the City University of Hong Kong. He is the Co-Chair of Artificial Intelligence Council for World Economic Forum Center for the Fourth Industrial Revolution, Fellow of the Institute of Electrical and Electronics Engineers (IEEE), Times 100 in 2013, WIRED 25 Icons, and followed by over 50 million audience on social media.
In the field of artificial intelligence, Dr. Lee built one of the first game playing programs to defeat a world champion (1988, Othello), as well as the world's first large-vocabulary, speaker-independent continuous speech recognition system. Dr. Lee founded Microsoft Research China, later renamed Microsoft Research Asia, which was named as the hottest research lab by MIT Technology Review. While with Apple, Dr. Lee led AI projects in speech and natural language, which have been featured on Good Morning America on ABC Television and the front page of Wall Street Journal. He has authored 10 U.S. patents, and more than 100 journal and conference papers. Altogether, Dr. Lee has been in artificial intelligence research, development, and investment for more than 30 years. His New York Times and Wall Street Journal bestselling book AI Superpowers: China, Silicon Valley, and the New World Order (aisuperpowers.com) discusses US-China co-leadership in the age of AI as well as the greater societal impacts brought upon by the AI technology revolution. His new co-authored book AI 2041 will be published in fall 2021 exploring how artificial intelligence will change our world over the next twenty years.
Alán Aspuru-Guzik, PhD
Professor and Director, Vector Institute, University of Toronto
Professor Alan Aspuru-Guzik joined Harvard University in 2006. He leads the Aspuru-Guzik Research Group, a theoretical physical chemistry group in the Department of Chemistry and Chemical Biology at Harvard University. Their research focuses on the connections between quantum computation, quantum information, and chemistry; theoretical studies of energy and charge transfer in photosynthetic complexes and renewable energy materials; methods development for electronic structure theory: first-principles methods, density functional theory, and quantum Monte Carlo; and development of the Clean Energy Project, the world's largest distributed computing project for calculating the properties of candidate molecules for organic solar cells.
Donald Small, PhD
Director of pediatric oncology and professor, Johns Hopkins Medical Institute (JHMI)
Dr. Donald Small is Director of the Division of Pediatric Oncology at the Johns Hopkins Kimmel Cancer Center and the Kyle Haydock Professor of Oncology. He holds joint appointments in Pediatrics and Cellular and Molecular Medicine and Human Genetics. He also directs the Johns Hopkins/National Cancer Institute Pediatric Hematology/Oncology Fellowship program.
Dr. Small's laboratory was the first to clone the human FLT3 gene that is the most frequently mutated gene in acute myeloid leukemia (AML) and results in very poor chances of cure for these patients. The investigations of FLT3 led Dr. Small and his team to discover drugs able to inhibit the cancer-generating activity of this important gene. His laboratory showed that a new class of drugs known as tyrosine kinase inhibitors could kill FLT3-affected cells, thus developing one of the earliest molecularly targeted cancer therapies.
Klaus Witte, PhD
Member of the German Society of Pharmacology & Toxicology;
Member of the Ethics Commission II, University of Heidelberg
Stevan Djuric, PhD
Adjunct Professor at The University of Kansas;
Former head of the global AbbVie Medicinal Chemistry Leadership Team
Dr. Stevan Djuric was head of the global AbbVie Medicinal Chemistry Leadership Team at Abbott and is also responsible for the Discovery Chemistry and Technology organization within their Discovery organization and chemistry outsourcing activities. The group's current efforts are focused on new initiatives in the areas of high throughput synthesis and purification, to lead chemistry, chemical biology including target identification proteomics and new enabling technology identification and development. He was named an AbbVie Distinguished Research Fellow in 2015. During his tenure at Abbott Laboratories, Dr Djuric has been a Project Leader for groups in the Immunoscience, Metabolic Disease, and Anti Infective areas. Several of these programs have advanced compounds into clinical development and to the market including Abbott's proprietary rapamycin analog, Zotarolimus, currently licensed to Medtronics for use on their vascular stents, marketed in the United States and Europe. Dr Djuric has over 180 scientific publications, presentations and patents/applications pending.
Tudor Oprea, PhD
Professor and Chief, Translational Informatics Division, University of New Mexico
Dr. Oprea has thirty years of experience in machine learning, computational biology, chemistry and medicine, focused on data science, high quality data wrangling and informatics. Expert in drug & target repositioning, cheminformatics & QSAR, virtual screening, and hunting druggable targets. Co-inventor of G1, a selective GPER agonist that received IND clearance and orphan drug designation.Strong interest in Machine Learning/AI using in-depth knowledge mining of electronic medical records, literature, patents, drug labels and clinical trials. Two decades of conceptual development for chemical space exploration, including leadlike and druglike properties, and prioritization of understudied proteins & target selection. Biomedical background with clinical and pharmaco-physiological training.
Bud Mishra, PhD
Professor of Math and CS, Courant Institute,
Mathematical Sciences, New York University
Bud Mishra is a professor of computer science and mathematics at NYU's Courant Institute of Mathematical Sciences, professor of human genetics at Mt Sinai School of Medicine, and a professor of cell biology at NYU School of Medicine. Bud has a degree in Sciences from Utkal University, in Electronics and Communication Engineering from Indian Institute of Technology (IIT), Kharagpur, and MS and PhD degrees in Computer Science from Carnegie-Mellon University. Bud is also a visiting scholar at CSHL's Center for Quantitative Biology. From 2001-04, he was a professor at the Watson School of Biological Sciences, Cold Spring Harbor Lab (CSHL) and from 2003-2006, a Visiting Professor at Tata Institute of Fundamental Research (TIFR).
Bud is an IIT, Kharagpur Distinguished Alumnus, NYSTAR Distinguished Professor, AAAS Fellow (engineering: robotics, hardware verification and computational biology), IEEE fellow (robotics and automation) and a fellow of the ACM (computational biology and symbolic computation).
His other research activities, outside of computational and systems biology, take place in the newly created Laboratory for Entrepreneurship in Data Sciences (LEDS) focusing on challenges from Finance, Advertising and Ad Technology, Philanthropy, Biomedicine and Engineering. Somewhat immodestly (and with apologies to Albert Arnold "Al" Gore), the laboratory aims to reinvent the Internet of the future.
Ju Wang, PhD
Head of Biology
13+ years experience in molecular biology, cell biology, and immuno-oncology in GSK, Biotech, and academia
Xiao Ding, PhD
Head of Chemistry
10+ years experience in medicinal chemistry in Pharma (Roche & GSK). Proven track record to deliver key milestones for small molecule drug discovery including lead ID, PCC, and IND
Liena Qin
Head of PROTAC
Luoheng Qin, PhD
Director of Medicinal Chemistry
8+ years' experience in medicinal chemistry & project leadership in Eli Lilly, J&J and Jiangsu Hansoh Pharma
Yingtao Liu, PhD
Head of CADD
8+ years of experiences in local pharma/biotech and MNC, and multidisciplinary background, including biology, chemistry and informatics
Jimmy Yen-Chu Lin, PhD
CEO of Insilico Medicine Taiwan
  • 12+ year's experience in drug R&D
  • Led A*STAR, Harvard and MSD co-research project
Tzu-Lan Yeh, PhD
Senior Director, External Innovation and Strategic Alliance
Proven records in the filed of computational biology, structural biology, and pre-clinical drug development
Andrey Kukharenko, PhD, PMP
Director, Preclinical Development
11+ years experience in preclinical development & CMC management, regulatory compliance and registration
Xing Liang, PhD
Head of CMC
10+ years of experience in novel drug API process development and CMC project management at Roche and Cinkate
Qingyuan Meng, PhD
Project leader
5+ years biology experience in Amgen and 5 years postdoctoral experience in Columbia University and Albert Einstein College of Medicine